PHILADELPHIA, March 5, 2019 /PRNewswire/ -- Carisma Therapeutics Inc., a preclinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies based on chimeric antigen receptor macrophages, today announced that the Company's management will present at three upcoming investor and industry conferences:
William Blair 9th Annual Cancer Immunotherapy Conference ? Carisma's management will deliver a scientific presentation on March 20, 2019 at 9:55 am EST. The conference will be held at the Apella, Event Space Alexandria Center in New York, NY;
Alliance for Regenerative Medicine Cell & Gene Investment Day ? Carisma's management will participate in the conference in New York City and provide a corporate update on March 21, 2019, at 2:15 p.m. EST; and
Keystone Symposia on Molecular and Cellular Biology: Innate and Non-Classical Immune Cells in Cancer Immunotherapy ? Carisma's management will present in the Cellular Therapies and Biomarkers session on March 28, 2019 at 2:30 p.m. MST. The conference will be held at the Keystone Resort, Keystone, CO.
The Alliance for Regenerative Medicine Cell & Gene Investment Day is filmed and livestreamed from the meeting website at http://arminvestorday.com/webcast/.
About Carisma Therapeutics Inc.
Carisma Therapeutics Inc. is biopharmaceutical company bringing the power of adoptive cellular immunotherapy to solid tumor patients through a differentiated platform using chimeric antigen receptor macrophages. Carisma Therapeutics is headquartered in Philadelphia, PA. For more information, please see the Company's website at https://carismatx.com/.
Media Contact:
Deirdre Purdy for Carisma Therapeutics [email protected] 914-819-7870
4P-Pharma, a Lille-based clinical-stage startup studio focused on developing curative therapies for untreated serious diseases, announces that it has successfully secured a total capital of ?15 million in its second closing with participation from...
PROTEINA announced today that it has held a kickoff meeting with Professor Janghee Woo and his research team at Emory University School of Medicine in Atlanta, to begin global clinical validation of its flagship product, PPI PathFinder BCL2 Dx.
PPI...
Building on its commitment to identify strengths and gaps in the R&D pipeline for antivirals, the INTREPID Alliance, a consortium of innovative biopharmaceutical companies dedicated to accelerating antiviral treatments to help protect the world ahead...
AriBio Co., Ltd. (AriBio) announced authorisation from the European Medicines Agency (EMA) for POLARIS-AD (AR1001-ADP3-US01), a global, phase 3, early Alzheimer's disease clinical trial. EMA now aligns with the U.S. Food and Drug Administration (FDA)...
Celltrion USA announced today that it has signed an agreement with Express Scripts, one of the nation's leading pharmacy benefit managers (PBMs) negotiating on behalf of health plans covering more than 100 million people. The agreement, effective...